Abstract
BALB/c mice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by intravenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
Keywords: Integrin antagonist, AP25, indirect ELISA, pharmacokinetics, plasma protein binding rate, HPLC
Protein & Peptide Letters
Title:Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma
Volume: 20 Issue: 5
Author(s): Yongbing Li, Hanmei Xu, Jialiang Hu, Fengguo Zhang, Zhendong Liu, Chi Zhang, Yongjing Yang, Chunyan Pu, Linqiu Huang and Xin Wen
Affiliation:
Keywords: Integrin antagonist, AP25, indirect ELISA, pharmacokinetics, plasma protein binding rate, HPLC
Abstract: BALB/c mice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by intravenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
Export Options
About this article
Cite this article as:
Li Yongbing, Xu Hanmei, Hu Jialiang, Zhang Fengguo, Liu Zhendong, Zhang Chi, Yang Yongjing, Pu Chunyan, Huang Linqiu and Wen Xin, Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma, Protein & Peptide Letters 2013; 20 (5) . https://dx.doi.org/10.2174/0929866511320050012
DOI https://dx.doi.org/10.2174/0929866511320050012 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characterization of Particulate Drug Delivery Systems for Oral Delivery of Peptide and Protein Drugs
Current Pharmaceutical Design Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Activation of B Cells by a Dendritic Cell-Targeted Oral Vaccine
Current Pharmaceutical Biotechnology Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis
Current Pharmaceutical Design Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Current Drug Safety Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Retraction Notice: Current Management of Vomiting After Tonsillectomy in Children
Current Drug Safety The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry Alcohol Abuse and Pancreatic Diseases: An Overview
Recent Patents on Inflammation & Allergy Drug Discovery Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies
Current Drug Targets Ethnobotanical Survey of Medicinal Plants used to Treat Cardiovascular Disorders in Ghasemloo Valley of Urmia City
Cardiovascular & Hematological Agents in Medicinal Chemistry Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Proceedings of the 1<sup>st</sup> Puerto Rico Biobanking Workshop
Reviews on Recent Clinical Trials Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging